-
1
-
-
13544249943
-
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity
-
Ingelman-Sunberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics 2005; 5:6-13.
-
(2005)
Pharmacogenomics
, vol.5
, pp. 6-13
-
-
Ingelman-Sunberg, M.1
-
2
-
-
84857705331
-
Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance
-
Teh LK, Leif B. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 2012; 27:55-67.
-
(2012)
Drug Metab Pharmacokinet
, vol.27
, pp. 55-67
-
-
Teh, L.K.1
Leif, B.2
-
3
-
-
0742286803
-
Cytochrome P450 2D6: Overview and update on pharmacology, genetics, and biochemistry
-
Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, and biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 2004; 369:23-37.
-
(2004)
Naunyn-Schmiedebergs Arch Pharmacol
, vol.369
, pp. 23-37
-
-
Zanger, U.M.1
Raimundo, S.2
Eichelbaum, M.3
-
4
-
-
70449371633
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance
-
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Clin Pharmacokinet 2009; 48:761-804.
-
(2009)
Clin Pharmacokinet
, vol.48
, pp. 761-804
-
-
Zhou, S.F.1
-
5
-
-
84897022750
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 update
-
Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014; 95:376-382.
-
(2014)
Clin Pharmacol Ther
, vol.95
, pp. 376-382
-
-
Crews, K.R.1
Gaedigk, A.2
Dunnenberger, H.M.3
Leeder, J.S.4
Klein, T.E.5
Caudle, K.E.6
-
6
-
-
84876665512
-
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2D19 genotypes and dosing of tricyclic antidepressants
-
Hicks JK, Swen JJ, Thorn CF, Sangkul K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2D19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93:402-408.
-
(2013)
Clin Pharmacol Ther
, vol.93
, pp. 402-408
-
-
Hicks, J.K.1
Swen, J.J.2
Thorn, C.F.3
Sangkul, K.4
Kharasch, E.D.5
Ellingrod, V.L.6
-
7
-
-
84962294272
-
Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors
-
Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98:127-134.
-
(2015)
Clin Pharmacol Ther
, vol.98
, pp. 127-134
-
-
Hicks, J.K.1
Bishop, J.R.2
Sangkuhl, K.3
Muller, D.J.4
Ji, Y.5
Leckband, S.G.6
-
8
-
-
38349132802
-
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
-
Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83:234-242.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 234-242
-
-
Gaedigk, A.1
Simon, S.D.2
Pearce, R.E.3
Bradford, L.D.4
Kennedy, M.J.5
Leeder, J.S.6
-
9
-
-
84924348487
-
Copy number variations' effect on drug response still overlooked
-
Willard C. Copy number variations' effect on drug response still overlooked. Nat Med 2015; 21:206.
-
(2015)
Nat Med
, vol.21
, pp. 206
-
-
Willard, C.1
|